Who are Infinimmune's investors?

Infinimmune's investors include Civilization Ventures Management, Llc, Pear VC, Playground Global, RA Capital, Axial VC, Paladin Capital Group, Trammell Venture Partners (TVP).

Infinimmune

Founded 2022 · 22 employees on LinkedIn · 7 known investors

Find your way into Infinimmune

Paths you didn't know you had: your email and LinkedIn already hold routes to the Infinimmune team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Infinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.

AI & Machine Learning Biotech Medical Devices

Founders & leadership

Infinimmune was founded in 2022 by Lance Hepler, Katie Pfeiffer, Michael Gibbons, Wyatt McDonnell, and david jaffe.

Lance HeplerCo-Founder

Katie PfeifferCo-Founder, CTO

Michael Gibbons Co-FounderMichael Gibbons worked as a bioengineer on translational medicine research in skeletal muscle and orthopedics. He subsequently developed protein sequencing technology at Google and led sample preparation product development at 10x Genomics before founding Infinimmune, which discovers and develops antibody therapeutics.

Wyatt McDonnell Co-Founder and CEOWyatt McDonnell is co-founder and CEO of Infinimmune, a biotechnology company that develops antibody therapeutics for autoimmune and inflammatory diseases.

david jaffe Co-Founder2022–2026David Jaffe studied mathematics and transitioned into computational biology. He is founder of Infinimmune, which discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization.

David JaffeFounder

Mike GibbonsFounder

Investors · 7

Civilization Ventures Management, Llclisted by Civilization Ventures Management, LlcTiburon · $1M – $10M

How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Pear VClisted by Pear VCSan Francisco · $150K – $4M

How we know: pear.vc · open dataset · 5k.vc investor directory · Not right? Tell us

Playground Globallisted by Playground GlobalPalo Alto · $1M – $20M

How we know: Playground Global's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · Not right? Tell us

Axial VCreportedSan Francisco · $100K – $5M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Paladin Capital GroupreportedWashington · $100K – $5M

How we know: a partner's Signal profile · Not right? Tell us

Trammell Venture Partners (TVP)reportedAustin

How we know: a partner's Signal profile · Not right? Tell us

Related companies · 6

InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.

ImmuneeringImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.

ImmunaiImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Inmune BioINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.

ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

Companies working in the same space as Infinimmune.

Frequently asked questions

What does Infinimmune do?: Infinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Who founded Infinimmune?: Infinimmune was founded by Lance Hepler, Katie Pfeiffer, Michael Gibbons, Wyatt McDonnell, david jaffe in 2022.
Who are Infinimmune's investors?: Infinimmune's investors include Civilization Ventures Management, Llc, Pear VC, Playground Global, RA Capital, Axial VC, Paladin Capital Group, Trammell Venture Partners (TVP).